Alpha-Synuclein (α-Syn)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synuclein (α-Syn)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td><a href="/genes/snca">SNCA</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P37840" target="_blank">P37840</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/1XQ8" target="_blank">1XQ8</a>, <a href="https://www.rcsb.org/structure/6A6B" target="_blank">6A6B</a>, <a href="https://www.rcsb.org/structure/4R0P" target="_blank">4R0P</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>14 kDa (140 aa)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Presynaptic terminals, nucleus</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Synuclein family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/dementia-with-lewy-bodies">DLB</a>, <a href="/diseases/multiple-system-atrophy">MSA</a></td>
</tr>
</table>
Alpha-Synuclein (α-Syn)
Overview
Alpha-synuclein (α-Syn) is a 140-amino acid protein encoded by the [SNCA gene](/genes/snca) that is centrally involved in the pathogenesis of Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), collectively termed synucleinopathies [@spillantini1997]. Under pathological conditions, α-Syn misfolds, aggregates, and forms Lewy bodies and Lewy neurites, which are hallmark inclusions in the brains of patients with these disorders [@baba1998].
Alpha-synuclein is a natively unfolded protein that can adopt multiple conformational states, including α-helical structures upon membrane binding and β-sheet-rich conformations during aggregation. The propagation of α-Syn pathology follows a prion-like pattern, spreading from peripheral sites to the central nervous system and between brain regions in a stereotypic manner [@yamasaki2026].
SNCA Gene
The SNCA gene is located on chromosome 4q21.31 and consists of six exons. The protein is expressed primarily in neurons, particularly in presynaptic terminals, though lower expression is found in other cell types including oligodendrocytes and astrocytes. The promoter region contains binding sites for transcription factors that regulate tissue-specific expression.
Alternative Splicing
Multiple isoforms of α-Syn are generated through alternative splicing [@eliezer2001]:
- α-Syn-140: Full-length (140 aa) - predominant species in most tissues
- α-Syn-126: Exon 3 skipped (126 aa) - lacks central region, less aggregation-prone
- α-Syn-98: Exons 3 and 5 skipped (98 aa) - shortened, primarily in brain
- α-Syn-115: Alternative splice variant (115 aa) - rare isoform
The relative ratios of these isoforms may be altered in disease, and specific splice variants may have distinct aggregation propensities and functional effects. The 140-residue isoform is the most abundant and disease-relevant form.
Molecular Structure
Domain Architecture
Alpha-synuclein contains three distinct domains that mediate its diverse functions [@wood2006]:
N-Terminal Domain (1-60 aa)
- Amphipathic α-helical region upon membrane binding
- Contains 7 imperfect repeats of the KTKEGV motif
- Binds to acidic phospholipid membranes
- Mutation hotspots located here (A30P, E46K, H50Q, G51D, A53T)
- The repeat sequences mediate lipid binding and may facilitate vesicle clustering
Central Domain (61-95 aa)
- Hydrophobic NAC (Non-Aβ Component) region
- Critical for aggregation (residues 71-82, known as the "NACore")
- Forms the core of β-sheet structures in fibrils
- Highly prone to amyloid formation
- This region is protected in the fibril core and is resistant to proteolysis
C-Terminal Domain (96-140 aa)
- Acidic, proline-rich region
- Highly charged and flexible (15 Asp/Glu residues)
- Regulates aggregation propensity (inhibitory)
- Contains phosphorylation sites (Ser129, Ser87)
- The acidic tail may act as a "chaperone" preventing aggregation
Natively Unfolded
In solution at physiological pH, α-Syn exists as a natively unfolded monomer with little persistent secondary structure. This disordered state allows the protein to interact with multiple partners and adopt different conformations based on environmental conditions.
α-Helical Conformation
Upon binding to lipid membranes, α-Syn adopts an α-helical conformation, particularly in the N-terminal region [5]. This membrane-bound form may be functionally relevant for normal synaptic vesicle regulation. The helical structure spans approximately residues 1-100 and is organized as two antiparallel helices separated by a short linker.
β-Sheet Aggregation
Under pathological conditions, α-Syn converts to β-sheet-rich oligomers and fibrils [@conway2000]. This conformational transition is central to disease pathogenesis and can be seeded by pre-existing aggregates. The fibrils have a characteristic cross-β structure with strands perpendicular to the fibril axis.
Post-Translational Modifications
Pathological modifications regulate α-Syn aggregation and toxicity [@tenreiro2014]:
| Modification | Site | Effect on Pathology |
|--------------|------|---------------------|
| Phosphorylation | Ser129, Ser87, Tyr125, Tyr133 | Ser129 phosphorylation is hallmark (~90% in LB) |
| Ubiquitination | Multiple Lys residues | Degradation signals, found in LB [@martinez2003] |
| Sumoylation | Lys102, Lys96 | Alters aggregation propensity |
| Truncation | C-terminus (residues 1-120, 1-110) | Generates aggregation-prone fragments |
| Nitration | Tyr39, Tyr125, Tyr133 | Promotes aggregation, found in PD brain |
| Oxidation | Met1, Met5, Met116, Met127 | Promotes aggregation, oxidative stress marker |
| Glycation | Multiple sites | Cross-linking, advanced glycation end-products |
Phosphorylation at Ser129 is the most specific pathological modification, found in over 90% of Lewy body α-Syn. This modification is mediated by several kinases including casein kinases and PLK3, and may serve as a useful biomarker.
Normal Physiological Functions
Synaptic Vesicle Regulation
Alpha-synuclein plays important roles in synaptic function [@culla2011]:
- Regulates synaptic vesicle pools: Controls the reserve pool of synaptic vesicles
- Modulates dopamine release: Influences quantal content and release probability
- Influences vesicle trafficking: Affects vesicle endocytosis and recycling
- Participates in synaptic plasticity: Required for long-term potentiation
The protein is highly enriched at presynaptic terminals where it may constitute up to 1% of total soluble protein. Its interaction with synaptic vesicles is regulated by membrane lipid composition and phosphorylation state.
Membrane Binding
The N-terminal domain binds to synaptic vesicles [5]:
- Phospholipid membranes (especially acidic phospholipids)
- Synaptic vesicle clustering and organization
- May act as a molecular chaperone for membrane fusion proteins
- Fatty acid binding may regulate its function
Neuroprotection
Under normal conditions, α-Syn may provide neuroprotective functions:
- Antioxidant properties: May scavenge reactive oxygen species
- Anti-apoptotic effects: Interacts with apoptotic pathways
- Chaperone activity: Helps prevent protein aggregation
- DNA protection: Binds to DNA and may protect against damage
SNARE Complex
Alpha-synuclein interacts with the SNARE complex:
- Facilitates SNARE complex assembly
- Modulates neurotransmitter release
- Critical for synaptic function
- May regulate the size of the readily releasable pool
α-Syn can bind metal ions, which may regulate its function and aggregation [@devine2011]:
- Iron: Promotes aggregation, elevated in PD brain
- Copper: Binds with high affinity, affects folding
- Calcium: May promote membrane binding
Aggregation Mechanisms
Misfolding and Oligomerization
The aggregation of α-Syn follows a nucleation-dependent mechanism:
Mermaid diagram (expand to render)
Toxic Oligomeric Species
Soluble oligomeric intermediates are considered the primary toxic species [@cao2012]:
- Protofibrils: Larger oligomeric assemblies, can be membrane-permeable
- Annular oligomers: Pore-like structures that disrupt membranes
- Spherical oligomers: Common early intermediates
- Fibrillar oligomers: Prefibrillar aggregates on the pathway to fibrils
These oligomers can:
- Disrupt membrane integrity through pore formation
- Impair synaptic function and plasticity
- Cause mitochondrial dysfunction and energy failure [@tsika2010]
- Activate endoplasmic reticulum stress pathways [@guo2008]
- Spread between cells and seed further aggregation
Strain Diversity
Like other amyloid proteins, α-Syn can form distinct strains that correlate with clinical phenotypes [@sideris2026]:
- Parkinson's disease type: Classic Lewy body pathology
- Multiple system atrophy type: More aggressive, glial cytoplasmic inclusions (GCIs)
- Dementia with Lewy bodies type: Cortical Lewy bodies, less aggressive
- Hallmark pattern A (HBPA): Highly aggregated, protease-resistant
The strain concept explains how the same protein can produce different clinical syndromes.
Cell-to-Cell Spread
Alpha-synuclein pathology propagates in a prion-like manner [2]:
- Released from affected neurons via exocytosis or extracellular vesicles
- Internalized by neighboring cells through various mechanisms (receptor-mediated, endocytosis)
- Seeds aggregation of endogenous α-Syn through templated conversion
- Spreads along neural networks following connectivity patterns
Disease Role in Parkinson's Disease
Lewy Bodies
The hallmark pathological inclusion in PD is the Lewy body [@spillantini1997]:
- Structure: Spherical cytoplasmic inclusions, 5-25 μm diameter
- Composition: Primarily fibrillar α-Syn with other proteins
- Modifications: Ubiquitinated and heavily phosphorylated at Ser129
- Cellular context: Surrounded by damaged organelles, displaced nuclei
Lewy Neurites
Abnormal neuritic processes containing α-Syn aggregates:
- Distal portions of axons are particularly affected
- Contribute to connectivity loss and circuit dysfunction
- May precede Lewy body formation in disease progression
Braak Staging
The progression of α-Syn pathology follows a predictable pattern:
- Stage 1-2: Brainstem (dorsal motor nucleus of vagus, locus coeruleus)
- Stage 3-4: Limbic system (amygdala, hippocampus, anterior olfactory nucleus)
- Stage 5-6: Neocortex (primary sensory and association areas)
This progression correlates with clinical symptoms - brainstem involvement precedes motor symptoms, while cortical involvement correlates with dementia.
Braak Hypothesis
The dual-hit hypothesis suggests:
- Entry route: Pathogen may enter via olfactory or nasal route
- First hit: Spreads to brainstem via vagus nerve
- Second hit: Later spreads to cortex
- This explains the clinical progression from non-motor to motor to cognitive symptoms
Other Synucleinopathies
Dementia with Lewy Bodies (DLB)
- Cortical Lewy bodies prominent [@baba1998]
- Fluctuating cognition with prominent attention deficits
- Visual hallucinations (often early, detailed)
- Parkinsonism (typically symmetric onset)
- Core feature: REM sleep behavior disorder (RBD)
- Rapid eye movement behavior disorder often precedes cognitive symptoms by years
Multiple System Atrophy (MSA)
- Oligodendroglial inclusions (GCIs) - distinct from Lewy bodies
- More aggressive progression than PD
- Motor symptoms (MSA-P: parkinsonian, MSA-C: cerebellar)
- Autonomic dysfunction prominent (orthostatic hypotension, urinary dysfunction)
- Poor levodopa response
Pure Autonomic Failure (PAF)
- Orthostatic hypotension as primary feature
- Peripheral α-Syn pathology primarily
- May progress to PD/DLB in some cases (approximately 20%)
REM Sleep Behavior Disorder (RBD)
- Loss of REM sleep atonia
- Dream-enacting behaviors (acting out dreams)
- Often prodrome to synucleinopathy
- High conversion rate to PD/DLB/MSA (over 80% after 10 years)
- Represents a window for neuroprotective intervention
Therapeutic Strategies
Immunotherapies
Active Immunization
- PD01A (Affiris): Peptide vaccine targeting α-Syn, showed antibody response
- ACI-35 (Affiris): Liposome-based vaccine targeting phosphorylated α-Syn
- Generates antibodies that may clear pathological protein
Passive Immunization
- Prasinezumab (PRX002, Roche): Anti-α-Syn antibody, mixed results in Phase 2
- Cinpanemab (BIIB054, Biogen): Antibody targeting oligomers, discontinued after Phase 2
- UCB-7935 (UCB): Phase 1 results showed good safety profile
Aggregation Inhibitors
- Anle253b: Dual Aβ/tau inhibitor, in development
- Curcumin derivatives: Natural compound with aggregation inhibition
- Epigallocatechin-3-gallate (EGCG): Green tea polyphenol, in trials
- Small molecules targeting the NACore: Specific aggregation blockers
Small Molecule Approaches
- Dopamine modulation: May reduce toxic species formation
- Metal chelation: Targeting iron and copper interactions
- Neurturin: GDNF analog for neuroprotection
- mTOR inhibitors: Promote autophagy of α-Syn
Gene Therapy
- AAV2-GAD: Glutamic acid decarboxylase gene
- AAV2-AADC: Aromatic L-amino acid decarboxylase
- Gene silencing: ASOs and RNAi targeting SNCA [@cheng2025]
- α-Syn reduction: Viral vector delivery of shRNA
Cell Replacement
- Cell transplantation: Fetal dopamine neurons (historical)
- iPSC-derived neurons: Patient-specific, in development
- Growth factors: GDNF, neurturin delivery
- Stem cell-derived dopamine neurons: Clinical trials ongoing
Emerging Approaches
- Protein replacement: Delivery of functional α-Syn
- Molecular chaperones: Enhance proper folding
- Autophagy enhancers: mTOR-independent pathways
- Exosome-based delivery: Cell-derived vesicles for therapy
Biomarkers
Cerebrospinal Fluid
- Total α-Syn: Decreased in PD (released from damaged neurons)
- Oligomeric α-Syn: Increased, more specific for synucleinopathy
- Phosphorylated Ser129 α-Syn: Disease-specific, most promising
- α-Syn/β-Syn ratio: Potential diagnostic utility
Blood Biomarkers
- NfL: Neurofilament light chain - general neurodegeneration marker
- p-Ser129 α-Syn: Ultra-sensitive assays now available [3]
- Total α-Syn: Variable results, affected by blood cell contamination
Imaging
- DatSCAN: Dopamine transporter imaging - shows presynaptic deficit
- MIBG imaging: Cardiac sympathetic denervation - specific for Lewy body disease
- Transcranial sonography: Substantia nigra hyperechogenicity
- PET ligands: Emerging α-Syn specific tracers in development
Seed Amplification Assays
- RT-QuIC: Real-time quaking-induced conversion - highly sensitive
- PMCA: Protein misfolding cyclic amplification
- Very sensitive for early detection, even in prodromal stages [4]
- Can detect pathology in CSF, tissue, and blood
Genetics
Mutations
Missense Mutations
- A53T: Early-onset, aggressive PD, accelerated aggregation
- A30P: Reduced membrane binding, slower aggregation
- E46K: Increased aggregation, Lewy body disease
- H50Q: Increased aggregation, progressive parkinsonism
- G51D: Early-onset, atypical features, rapid progression
- A53V: Less common, variable presentation
Gene Duplication/Triplication
- SNCA duplication: Variable penetrance, dose-dependent
- SNCA triplication: Early-onset, severe, complete penetrance
- The triplication explains that increased expression alone can cause disease
Risk Factors
- SNCA polymorphisms: Multiple risk variants identified in GWAS
- GBA: Glucocerebrosidase mutations - major risk factor
- LRRK2: Leucine-rich repeat kinase 2 - some variants increase risk
- PARKIN, PINK1, DJ-1: Mitochondrial genes - recessive parkinsonism
- MAPT: Tau gene - interacts with α-Syn pathology
Interactions
Protein Partners
| Partner | Interaction | Functional Effect |
|---------|-------------|-------------------|
| Synphilin-1 | Binding | Lewy body formation |
| Tau | Co-aggregation | Cross-seeding, combined pathology |
| Hsp70 | Chaperone | Aggregation inhibition |
| Hsp90 | Chaperone | Proteostasis regulation |
| NSF | SNARE interaction | Synaptic vesicle recycling |
| CSPα | Chaperone | Synaptic function |
| D2/D3 dopamine receptors | Binding | Modulates receptor signaling |
| Mitochondrial proteins | Various | Mitochondrial dysfunction |
Lipid Interactions
- Phosphatidylinositol, phosphatidylserine
- Fatty acids (palmitate, oleate)
- Membrane rafts
Recent Research (2025-2026)
Recent studies have advanced our understanding of α-synuclein pathology and therapeutic strategies [1-7]:
Propagation and Seeding Mechanisms
- α-Syn strains: Different strains of α-synuclein show distinct biological activities and may explain clinical variability in synucleinopathies
- Cell-to-cell transmission: New insights into the mechanisms of α-syn propagation have revealed novel therapeutic targets
Biomarker Advances
- Blood biomarkers: Ultra-sensitive assays now enable detection of α-syn pathology in blood samples, improving accessibility
- Seed amplification: RT-QuIC and PMCA technologies continue to show promise for early diagnosis
Therapeutic Developments
- Immunotherapy: Anti-α-synuclein antibodies continue in clinical trials with updated protocols
- Gene therapy: Novel delivery methods for ASO and RNAi approaches are being explored
Exosome Research
- Exosome-mediated delivery: Studies on exosome nanodelivery systems for α-syn targeting show promise
- Zombosomes: Novel anucleated cellular vehicles that spread α-syn pathology
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease) — Primary synucleinopathy
- [Lewy Body Dementia](/diseases/lewy-body-dementia) — Synucleinopathy with dementia
- [SNCA Gene](/genes/snca) — Gene encoding alpha-synuclein
- [Multiple System Atrophy](/diseases/multiple-system-atrophy) — Aggressive synucleinopathy
- [Synucleinopathies](/diseases/alpha-synucleinopathies) — Category of diseases with alpha-synuclein pathology
- [Tau Protein](/proteins/tau) — Another key protein in neurodegeneration
- [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies) — Cortical Lewy body disease
External Links
- [SNCA Gene - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/6622) - Official gene information
- [Alpha-Synuclein - UniProt](https://www.uniprot.org/uniprotkb/P37840) - Protein sequence and structure
- [Alpha-Synuclein and Parkinson's - Nature Reviews](https://www.nature.com/articles/nrn.2016.125) - Review article
- [Michael J. Fox Foundation - Parkinson's Research](https://www.michaeljfox.org/) - Patient advocacy and research funding
- [Allen Human Brain Atlas - SNCA Expression](https://human.brain-map.org/microarray/search/show?search_term=SNCA)
- [Allen Cell Type Atlas - SNCA](https://celltypes.brain-map.org/)
- [Allen Mouse Brain Atlas - SNCA](https://mouse.brain-map.org/)
- [BrainSpan Atlas of the Developing Human Brain](https://www.brainspan.org/)
<!-- scidex-demo:diagram:start -->
Pathway Diagram
Mermaid diagram (expand to render)
<!-- scidex-demo:diagram:end -->
<!-- scidex-demo:links:start -->
SciDEX Links
- [Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — score 0.78; target APOE; neurodegeneration.
- [SASP-Driven Aquaporin-4 Dysregulation](/hypothesis/h-807d7a82) — score 0.78; target AQP4; neurodegeneration.
- [SASP-Mediated Cholinergic Synapse Disruption](/hypothesis/h-1acdd55e) — score 0.76; target MMP2/MMP9; neurodegeneration.
- [Circadian Clock-Autophagy Synchronization](/hypothesis/h-b7898b79) — score 0.76; target CLOCK; neurodegeneration.
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analyses/SDA-2026-04-01-gap-008)
- [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analyses/SDA-2026-04-01-gap-009)
- [APOE4 structural biology and therapeutic targeting strategies](/analyses/SDA-2026-04-01-gap-010)
<!-- scidex-demo:links:end -->